Skip to Content

Press Releases

November 19, 2026 7:00 AM EST

Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)

November 18, 2026 6:03 PM EST

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

November 17, 2026 7:00 AM EST

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications

November 12, 2026 5:00 PM EST

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

November 8, 2026 4:00 PM EST

CIDEBsiRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

November 2, 2026 4:05 PM EST

Regeneron Announces Investor Conference Presentations

October 30, 2026 6:30 AM EDT

Regeneron Reports Third Quarter 2026 Financial and Operating Results

October 26, 2026 7:00 AM EDT

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

October 25, 2026 5:15 AM EDT

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

October 16, 2026 7:00 AM EDT

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Back to top